Free Trial

DermTech (DMTK) Stock Price, News & Analysis

-0.14 (-27.99%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.15 million shs
Average Volume
185,473 shs
Market Capitalization
$12.59 million
P/E Ratio
Dividend Yield
Price Target

DermTech MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
560.0% Upside
$2.38 Price Target
Short Interest
10.13% of Float Sold Short
Dividend Strength
News Sentiment
-0.23mentions of DermTech in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.26) to ($2.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.58 out of 5 stars

Medical Sector

863rd out of 918 stocks

Medical Laboratories Industry

18th out of 19 stocks

DMTK stock logo

About DermTech Stock (NASDAQ:DMTK)

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DMTK Stock Price History

DMTK Stock News Headlines

BTIG Downgrades DermTech (DMTK)
What Analysts Are Saying About DermTech Stock
DermTech to Slash 56% of Workforce, Explore Options
DermTech, Inc. (DMTK)
Recap: DermTech Q4 Earnings
DermTech Reports Fourth-Quarter 2023 Financial Results
DermTech Q4 2023 Earnings Preview
DermTech International Registered Shs
See More Headlines
Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$15.30 million
Book Value
$1.67 per share


Free Float
Market Cap
$12.59 million
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin Sun M.B.A. (Age 46)
    CFO, Treasurer & Secretary
    Comp: $461.92k
  • Mr. Ray Akhavan Esq. (Age 55)
    J.D., General Counsel
    Comp: $413.06k
  • Mr. Bret Christensen (Age 53)
    President, CEO & Director
  • Mr. William W. Zondler
    Chief Information Officer
  • Mr. Steve E. Kunszabo
    Senior Director of Investor Relations
  • Ms. Jennifer Eilemberg
    Chief Compliance Officer
  • Dr. Burkhard Jansen M.D. (Age 58)
    Chief Medical Affairs Officer
    Comp: $419.8k
  • Dr. Loren Clarke M.D.
    Chief Medical Officer
  • Dr. Steven Stone Ph.D.
    Senior Vice President of Research & Development
  • Mr. Mark Aguillard
    Chief Commercial Officer

DMTK Stock Analysis - Frequently Asked Questions

Should I buy or sell DermTech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DMTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DMTK, but not buy additional shares or sell existing shares.
View DMTK analyst ratings
or view top-rated stocks.

What is DermTech's stock price target for 2024?

3 brokerages have issued twelve-month target prices for DermTech's shares. Their DMTK share price targets range from $0.63 to $5.00. On average, they predict the company's share price to reach $2.38 in the next twelve months. This suggests a possible upside of 560.0% from the stock's current price.
View analysts price targets for DMTK
or view top-rated stocks among Wall Street analysts.

How have DMTK shares performed in 2024?

DermTech's stock was trading at $1.75 at the beginning of the year. Since then, DMTK shares have decreased by 79.4% and is now trading at $0.3601.
View the best growth stocks for 2024 here

When is DermTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our DMTK earnings forecast

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02. The firm had revenue of $3.92 million for the quarter, compared to the consensus estimate of $4.05 million. DermTech had a negative trailing twelve-month return on equity of 138.79% and a negative net margin of 572.19%.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

Who are DermTech's major shareholders?

DermTech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Texas Capital Bank Wealth Management Services Inc (0.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Mutual Insurance Co Donegal, Ramin Akhavan, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends

How do I buy shares of DermTech?

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DMTK) was last updated on 5/21/2024 by Staff

From Our Partners